Glenmark Pharmaceuticals expands U.S. OTC market presence with Olopatadine Eye Drops
Glenmark secures FDA approval for its OTC Olopatadine Hydrochloride eye drops, expanding its U.S. presence in the $50.7M allergy relief market. Read More
Glenmark Therapeutics takes on Pataday with new OTC eye solution—what you need to know
Glenmark Therapeutics Inc., USA, has launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC), marking a significant development in the over-the-counter eye care market. This new ... Read More